1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. Somatostatin Receptor

Somatostatin Receptor

SSTRs; SSTR

Somatostatin receptors (SSTR1, 2A and B, 3, 4 and 5) belong to the G protein coupled receptor family. Somatostatin receptors are expressed in a variety of human tumors, including most tumors of neuroendocrine origin, breast tumors, certain brain tumors, renal cell tumors, lymphomas, and prostate cancer. Somatostatin triggers cytostatic and cytotoxic effects and has a general inhibitory effect on secretion mediated through its interaction with somatostatin receptors.

The SSTRs 1-4 display weak selectivity for somatostatin-14 binding, whereas SSTR5 is somatostatin-28-selective. Based on structural similarity and reactivity for octapeptide and hexapeptide somatostatin receptor analogs, SSTRs 2, 3 and SSTR5 belong to a similar somatostatin receptor subclass; SSTRs 1-4 react poorly with these analogs and belong to a separate subclass. All five somatostatin receptors are functionally coupled to inhibition of adenylyl cyclase via pertussis toxin-sensitive guanosine triphosphate (GTP)-binding proteins. mRNA for SSTRs 1-5 is widely expressed in brain and peripheral organs and displays an overlapping but characteristic pattern that is subtype-selective and tissue- and species-specific. All pituitary cell subsets express SSTR2 and SSTR5, with SSTR5 being more abundant. Individual pituitary cells coexpress multiple somatostatin receptor subtypes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS13829
    SSTR4 Human Pre-designed siRNA Set A
    Inhibitor

    SSTR4 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SSTR4 Human Pre-designed siRNA Set A
    SSTR4 Human Pre-designed siRNA Set A
  • HY-RS13823
    SSTR2 Human Pre-designed siRNA Set A
    Inhibitor

    SSTR2 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SSTR2 Human Pre-designed siRNA Set A
    SSTR2 Human Pre-designed siRNA Set A
  • HY-P10239
    Tyr3-Octreotate
    Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Tyr3-Octreotate
  • HY-123460
    BN-81674
    Antagonist
    BN-81674 is a somatostatin analogue and a selective antagonist of the non-peptide human somatostatin sst3 receptor (Ki=0.92 nM). In addition, BN-81674 reversed the inhibition of cyclic AMP accumulation induced by 1 nM somatostatin through the sst3 receptor with an IC50 value of 0.84 nM. BN-81674 can be used in cancer research.
    BN-81674
  • HY-P1959
    Lanreotide
    Activator
    Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome.
    Lanreotide
  • HY-P0036S2
    Octreotide-d8
    Agonist
    Octreotide-d8 (SMS 201-995-d8) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly.
    Octreotide-d<sub>8</sub>
  • HY-159825
    Branosotine
    Agonist
    Branosotine (compound 1-1) is a potent agonist of somatostatin receptor (SSTR2), with the EC50 of <0.1 nM.
    Branosotine
  • HY-164040
    Zavolosotine
    Agonist
    Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC50 <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model.
    Zavolosotine
  • HY-139347A
    Mazisotine tartrate
    Agonist
    SSTR4 agonist-1 tartrate (Preparation 4) is a SSTR4 agonist.
    Mazisotine tartrate
  • HY-157303
    SSTR5 antagonist 3
    Antagonist
    SSTR5 antagonist 3 (Compound 23) is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with low hERG inhibition. SSTR5 antagonist 3 exhibits potency with IC50 values of 2.8 nM and 1.4 nM in human and mouse, respectively. SSTR5 antagonist 3 can be used for the research of anti-gallstone.
    SSTR5 antagonist 3
  • HY-P1207
    BIM 23052
    Agonist
    BIM 23052 is a somatostatin receptor 5 agonist. BIM 23052 can induce gastric emptying.
    BIM 23052
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.